Sustainability Accounting Standards Board (SASB) Index

Code	Metrics	Sanofi's Disclosures	Comments
Safety of Clinical Trial Participants			
HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	• Post-Trial Access Policy • Incidental Findings • Access to Clinical Trial Data • Clinical Study Transparency Policy • Clinical Trial Results • Patient Support • Policy Position on Minority Diversity in Human Clinical Trials • Medical Ethics, Bioethics and Clinical Trials • URD: Chapter 4 p.39 • Integrated Report	All our clinical trials are run in accordance with the Principles of Good Clinical Practice (GCP) and international ethical standards, in particular the Helsinki Declaration on ethical principles regarding human experimentation.
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI); and (2) Official Action Indicated (OAI)	• Pharmacovigilance • Chapter 4 p.35	Sanofi systematically aligns on the most exacting standards of Good Pharmacovigilance Practices. In 2021, 41 audits and 4 inspections have been conducted on Pharmacovigilance.
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	• Form 20-F p.139	Sanofi and its subsidiaries disclose their involvement in litigation, arbitration and other legal proceedings.
Access to Medicines			
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	• Access to Healthcare • Access to Healthcare for the most vulnerable • Addressing the Needs of Rare Disease Patients around the World • Chapter 4 p.25 • Integrated Report	Sanofi's strategy of improving access to healthcare for the underserved is as much about ending global epidemics of infectious diseases and avoiding their resurgence, as it is about meeting the growing needs of patients suffering from non-communicable diseases. Sanofi helps patients

			access unique therapies, regardless of their location and financial situation, by working closely with national health services, government agencies and private insurers, as well as patient associations. Sanofi Global Health will operate in the **40 countries** with some of the lowest gross domestic product (GDP) per capita, and will offer **30 of our most essential medicines.**
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	• Fighting Malaria • Fighting Neglected Tropical Diseases • Fighting Tuberculosis • Chapter 4 p.25 • Integrated Report	Sanofi and the World Health Organization (WHO) have joined forces in the fight against NTDs since 2001. Sanofi is also at the forefront by developing new treatment options for Tuberculosis and Malaria diseases. The list of medicines and vaccines is available here.
Affordability & Pricing			
HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	• Form 20-F p.139	Patent litigation of Cerdelga®
HC-BP-240b.2	Percentage change in: (1) average list price and (2)	• Chapter 4 p. 28	

	average net price across U.S. product portfolio compared to previous year	• Prescription Medicine Pricing Principles	
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Not reported	
Drug Safety			
HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	• FDA's MedWatch Safety Alerts for Human Medical Products database • Form 20-F p.68	Zantac OTC recall
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	• FDA Adverse Event Reporting System	
HC-BP-250a.3	Number of recalls issued, total units recalled	• Chapter 4 p.35	In 2021, Sanofi conducted 38 recalls (39 in 2020 and 45 in 2019).
HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	• Pharmaceuticals in the environment • Chapter 4 p.55 • Planet Mobilization	Sanofi focuses particular attention on the challenge of preventing pharmaceuticals from entering the environment. Sanofi is committed to minimize the potential environmental impacts of our medicines through its "Planet Mobilization" program.
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	• Chapter 4 p.35	In 2021, Sanofi has received 190 regulatory inspections, of which 13 were conducted by the US FDA.

Counterfeit Drugs			
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	• Fight Against Falsified Medicines and Illicit Trafficking • Serialization: Medicine Identification, Authentication & Traceability	
HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	• Fight Against Falsified Medicines and Illicit Trafficking	Sanofi has training programs for employees, public health agents, customs officials and police officers from around the world. There has been a focus on internal awareness among sales forces as well as quality and supply chain representatives to better detect malicious acts (theft, falsification, illicit diversion) involving Sanofi products, and to put in place mitigation measures within the framework of an end-to-end product security program.
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	• Fight Against Falsified Medicines and Illicit Trafficking	Sanofi cooperates for instance with Interpol Operation Pangea and Europol Operation Shield.
Ethical Marketing			
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	• Promotional Practices • Form 20-F p.139	Sanofi and its subsidiaries disclose their involvement in litigation, arbitration and other legal proceedings.
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	• Promotional Practices • Code of Ethics	The core mission of our promotional activities is to provide quality

			information about the product presented in compliance with the marketing authorization for that product, and to promote correct use of the product among healthcare professionals.
Employee Recruitment, Development & Retention			
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	• Chapter 4 p.13	
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	• Chapter 4 p.13 • Integrated Report • ESG Key Performance Indicators	
Supply Chain Management			
HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	• Chapter 4 p.33-35	For all manufacturing, supply and distribution of our pharmaceutical products and vaccines, our facilities hold the manufacturing licenses and GxP certificates issued by the appropriate health authorities (FDA, EMEA, WHO…)
Business Ethics			
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with	• Form 20-F p.139	Sanofi and its subsidiaries disclose their involvement in litigation, arbitration and

	corruption and bribery		other legal proceedings.
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	• Relations with Healthcare professionals • Service Engagements with Scientific Experts	
Activity Metric			
HC-BP-000.A	Number of patients treated	• Access to Healthcare • ESG Key Performance Indicators • Integrated report	Considering the size of our product portoflio, we do not disclose patient demographic except for specific product, market segment or geographies. For instance, we estimate that half a billion people are vaccinated every year with our vaccines. We also track the number of patients reached by our Sanofi Global Health Programs and report on progress in our quarterly results.
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	• (1) Form 20-F p.17-27 • (2) Research and Development • Integrated Report	

SMART LINKS:

- Sanofi Website
- Document Center
- Integrated Report 2021
- Annual Report on Form 20-F 2021
- Universal Registration Document (in French)
- Declaration of Extra-Financial Performance (Chapter 4 of the Universal Registration Document)